Rhythm Pharmaceuticals (RYTM) CEO awarded RSUs and 107,850 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

RYTM Pharmaceuticals’ President and CEO David P. Meeker reported equity awards consisting of restricted stock units and stock options. On February 11, 2026, he received 71,900 restricted stock units, each representing the right to receive one share of common stock. These units vest 25% each on February 1, 2027, 2028, 2029 and 2030.

On the same date, he was also granted 107,850 stock options with an exercise price of $98.47 per share. These options vest in 16 substantially equal quarterly installments, based on completing each three full months of successive service after the grant date. Both awards are held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Meeker David P

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	71,900	$0.00	--
Grant/Award	Stock Options (Right to Buy)	107,850	$0.00	--

Holdings After Transaction: Restricted Stock Units — 71,900 shares (Direct); Stock Options (Right to Buy) — 107,850 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Form 4 Insider Transactions: What Each Field Means →

02/13/2026 - 05:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meeker David P

(Last)

(First)

(Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/11/2026		A		71,900		⁽²⁾	⁽²⁾	Common Stock	71,900	$0	71,900	D
Stock Options (Right to Buy)	$98.47	02/11/2026		A		107,850		⁽³⁾	02/10/2036	Common Stock	107,850	$0	107,850	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

3. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did RYTM’s CEO David Meeker report on this Form 4?

David Meeker reported receiving equity awards, not open-market trades. He was granted 71,900 restricted stock units and 107,850 stock options on February 11, 2026, both relating to Rhythm Pharmaceuticals common stock and held as direct beneficial ownership.

How many restricted stock units did RYTM grant to its CEO David Meeker?

Rhythm Pharmaceuticals granted David Meeker 71,900 restricted stock units. Each unit represents a contingent right to receive one share of common stock, subject to vesting over four years, with 25% of the total units vesting on each February 1 from 2027 through 2030.

What is the vesting schedule for David Meeker’s RYTM restricted stock units?

The 71,900 restricted stock units vest in four equal annual installments. Specifically, 25% of the units vest on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030, assuming continued service. The units have no expiration date.

What stock options did RYTM grant to CEO David Meeker and at what price?

David Meeker received 107,850 stock options with a $98.47 exercise price per share. These options give him the right to buy Rhythm Pharmaceuticals common stock if he chooses to exercise, subject to a multi-year vesting schedule tied to continued service after the February 11, 2026 grant date.

How do David Meeker’s RYTM stock options vest over time?

The 107,850 stock options vest and become exercisable in 16 substantially equal installments. Each installment vests after the completion of three full months of successive service to Rhythm Pharmaceuticals following the February 11, 2026 grant date, creating a quarterly vesting pattern.

Are David Meeker’s RYTM equity awards direct or indirect ownership?

Both the restricted stock units and stock options are reported as directly owned by David Meeker. The Form 4 lists the ownership form as “D” for direct, with no indication of indirect holdings through entities such as trusts, partnerships or family investment vehicles.